Mainstream reports centered on a large resting‑state MRI study of nearly 12,000 U.S. adolescents showing that commonly prescribed stimulants for ADHD (e.g., Adderall, Ritalin) appear to alter arousal and reward circuits more than the brain’s top‑down attention networks, suggesting their benefit may come from boosting norepinephrine‑driven alertness and dopamine‑mediated tolerance for mundane tasks rather than directly “fixing” attention networks. Coverage noted the study’s sample and authors’ interpretations and framed the findings as a revision to long‑held assumptions about stimulant mechanisms and clinical effects.
Missing from mainstream stories were important equity, clinical and methodological contexts that alternative sources flagged: racial and treatment‑access disparities (e.g., different diagnosis and medication rates and higher discontinuation among Black and Hispanic children), strong heritability estimates for ADHD alongside environmental contributors, and evidence that Black and Asian children receive fewer medications and outpatient visits. Also underreported were limits of resting‑state MRI for inferring clinical benefit, details on dose/type/duration of medication, long‑term functional outcomes, non‑stimulant and behavioral treatments, and socioeconomic/comorbidity factors that shape real‑world effectiveness — gaps readers would miss if they relied solely on the mainstream coverage. No prominent contrarian viewpoints were identified in the materials reviewed.